Gradual Decline in the Potency of Antipseudomonas Drugs: Evaluated by Retrospective Comparative studies of Susceptibility and Resistance Pattern of Antimicrobials against Pseudomonas Aeruginosa Isolates Obtained from Intensive Care Unit

Author : Somia Gul and Maria Ayub

Infectious disease accounts for the major cause of mortality and morbidity in past decays which create a serious and growing concern to treat communicable disease. P. aeruginosa ‘superbug’ responsible for hospital acquired nosocomial infections is versatile gram negative aerobe and pathogenecity caused by this ubiquitous organism is quite difficult to treat due to its rapid developing inherent resistance mechanism against antimicrobials and disinfectants. Variety of antimicrobials available to treat this notorious bacterium and there’s a gradual decline in sensitivity pattern upon development of new evolution of antimicrobials which reflects inadequate utilization of antimicrobial. The purpose of this study is to estimate the degree of potency of antipseudomonas drugs by retrospective comparative analysis of susceptibility and resistance pattern in public and private health sector of intensive care units and community acquired infections in past two years. About more than 200 isolates tested against wide range of antimicrobials. In past two years, there’s a gradual decline in susceptibility of amikacin (41%), gentamycin (45%), tobramycin (51%) and ciprofloxacin and emergence of initiation of resistance against carbapenems (23-29%), piperacillin (23%) & colisthemetate (33%) respectively. Quantitative estimation of this comparative studies we conclude antimicrobial resistance and susceptibility has close association with irrational utilization and inadequate evaluation of adaptive resistance mechanism against superbug called p.aeruginosa.

Full Text Attachment

Creative Commons License World Journal of Pharmaceutical Science is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at Permissions beyond the scope of this license may be available at